Seer’s Proteograph™ Product Suite identifies undiscovered links between protein variants and lung cancer progression
from Memorial Sloan Kettering Cancer Center found previously unknown associations between four protein isoforms and non-small cell lung cancer (NSCLC) progression, constituting potential novel, disease-relevant biomarkers, or therapeutic targets.
- from Memorial Sloan Kettering Cancer Center found previously unknown associations between four protein isoforms and non-small cell lung cancer (NSCLC) progression, constituting potential novel, disease-relevant biomarkers, or therapeutic targets.
- Importantly, the identified NSCLC-associated protein isoforms comprise structural variants of proteins that arise from distinct but related mRNAs produced from the same gene through the process of alternative splicing.
- Notably, discovery and quantification of such protein variants in a complex biological sample requires deep, unbiased interrogation of the proteome at peptide-level resolution.
- The Proteograph Product Suite makes it easy to add unbiased, deep, rapid proteomics studies at scale to any lab.